Opinion|Videos|January 21, 2025
Improvement in Standard of Care in Atopic Dermatitis
Panelists discuss how the standard of care in atopic dermatitis (AD) has evolved with recent advances in treatment, highlighting the use of assessment tools and scoring systems in clinical practice, and compare real-world outcomes with those seen in clinical trials for AD treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the standard of care in AD changed with recent advances?
- What assessment tools and scoring systems do you use in your practice?
- When looking at clinical outcomes, are you seeing results with AD treatments in your practice that are similar to what has been reported in clinical trials?
Advertisement
Related to this article
Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease (HR, 1.02).
Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
4
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
5